About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
2020 ASCO Virtual Direct™ Highlights
Boston
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
St. Louis
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
Basic Science
Jacksonville
Breast
Hematologic Oncology
Lung
GI
GU
GYN
Skin
Head&Neck
Basic Science
Philadelphia
GI
GU
Lung
Skin
Hematologic Oncology
Breast
Supportive/Palliative Care
Head&Neck
GYN
Denver
Breast
Hematologic Oncology
Lung
GU
Skin
GYN
Head&Neck
Basic Science
San Francisco
Breast
Lung
GU
Hematologic Oncology
Skin
GI
GYN
Head&Neck
Business
Las Vegas
GI
GU
Hematologic Oncology
Skin
Lung
Head&Neck
GYN
Business
San Juan
Breast
GI
Hematologic Oncology
Skin
GYN
Basic Science
Head and Neck
Supportive and Palliative Care
Business
Events
Skin
06:56
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Stage III Melanoma: Does Pembrolizumab Improve Recurrence-free Survival After Complete Resection of High-risk Disease?
FEATURING
William Sharfman
64 views
July 17, 2020
06:53
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Resected Stage III BRAF V600-mutant Melanoma: Is Dabrafenib + Trametinib an Effective Adjuvant Therapy Following Surgery With an Excellent Safety Profile?
FEATURING
William Sharfman
32 views
July 17, 2020
09:16
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Melanoma: Is There Significant Antitumor Activity for Low-dose Ipilimumab + Pembrolizumab Immediately Following Progression on PD-1 Ab in Melanoma?
FEATURING
William Sharfman
32 views
July 17, 2020
10:12
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Melanoma: Does Ipilimumab + PD-1 Have a Higher RR and OS vs. Ipilimumab Alone in Patients Resistant to PD-1?
FEATURING
William Sharfman
36 views
July 17, 2020
08:08
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Stage IV Melanoma: Is Lifileucel Effective and Does it Provide a Durable Response in Patients With High Baseline Disease Burden Who Progressed on Multiple Prior Therapies?
FEATURING
William Sharfman
107 views
July 17, 2020
